Drug Trial Radar · NCT07667621
A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Sep 15, 2026
Primary completion
Jul 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- University of South FloridaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Pfizer; Tampa General Hospital
- First posted
- Jun 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Prospective, single-site, open-label, non-controlled pilot study consisting of two parallel trials. Participants will receive rimegepant or zavegepant for acute migraine treatment during a single Emergency Department visit, with post-discharge follow-up through 28 days. Participants will be allocated to either the rimegepant trial or the zavegepant trial. The study design does not include a placebo or active comparator control group, and the two gepant study drugs are not designed to function as active comparator groups. The objective in this investigation is to examine relief from either rimegepant or zavegepant in separate parallel trials.
Conditions
- Migraine
- Migraine Disease
- Migraine in Adults
- Migraine Headache
- Acute Migraine
- Migraine Without Aura
- Migraine With Aura
Interventions
RimegepantDrug
Rimegepant 75 mg orally disintegrating tablet administered as a single dose during an Emergency Department visit for the acute treatment of migraine. The tablet is placed on or under the tongue and allowed to dissolve without water, consistent with FDA-approved labeling.
ZavegepantDrug
Zavegepant 10 mg nasal spray administered as a single spray into one nostril during an Emergency Department visit for the acute treatment of migraine. Administration is consistent with FDA-approved labeling
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain relief at 2 hours without rescue medicationTime frame: 2 hours post-study drug administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tampa General Hospital Emergency Room
Tampa, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.